ArticleBlood cancer journal2021
ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine.
Open access · goldAbstract read
In one paragraph
Article in Blood cancer journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 1 pooled it
6.6field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- Venetoclax-Based Regimens in Chronic Myelomonocytic Leukemia: A Systematic Review and Meta-Analysis.Acta haematologica · 2026Pooled it
- Comutation of asxl1 and IDH2R172K enhances leukemogenesis and correlates with epigenetic activation of MAPK and AP-1 in zebrafish.Blood advances · 2026Article
- Wired to Survive: How AML Cytogenetics Shape Apoptotic Dependence and Venetoclax Resistance.Genes · 2026Review
- Premature senescence impairs hematopoietic stem cell function during sickle cell disease in mice and humans.Science translational medicine · 2026Article
- Review
- Prognostic impact of ASXL1 mutations in acute myeloid leukemia treated with lower intensity therapy.Cancer · 2026Article
- Resistance to Targeted Therapy in AML: Current Challenges and Emerging Treatment Strategies.Journal of clinical medicine · 2026Review
- Venetoclax Plus Hypomethylating Agents for Treatment-Naïve Myelodysplastic Syndromes with Increased Blasts: A Prospective Multicenter Cohort Study.Blood and lymphatic cancer : targets and therapy · 2026Article
- Combinatorial BCL2/BCL2L1 expression predicts clinical response to ruxolitinib in myelofibrosis.Biomarker research · 2025Article
- [Efficacy of venetoclax combined with hypomethylating agents in the treatment of patients newly diagnosed with core binding factor acute myeloid leukemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Article
- Molecular predictors of response and survival in patients with relapsed/refractory acute myeloid leukemia following venetoclax plus hypomethylating agent therapy.Haematologica · 2025Article
- Better Response and Prognosis of Venetoclax Plus Hypomethylating Agents Over Intensive Chemotherapy in Young Adults With Newly Diagnosed ASXL1-Mutated Acute Myeloid Leukemia.Cancer medicine · 2025Article
- [Bioinformatic analysis of venetoclax sensitivity and resistance mechanisms in acute myeloid leukemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Article
- Case Report: Myelodysplastic/myeloproliferative neoplasm with concurrent SF3B1, ASXL1, JAK2 and CBL mutations and <15% bone marrow ringed sideroblasts.Frontiers in oncology · 2025Article
- Case Report: A familial hematological pedigree reveals VHL germline mutation as a principal predisposition factor with additional mutations modulating phenotypic heterogeneity.Frontiers in oncology · 2025Article
- Unveiling prognosis in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax through novel risk stratification.Leukemia research reports · 2025Review
- Factors affecting response and resistance to venetoclax in acute myeloid leukemia.Frontiers in oncology · 2025Review
- Potential Off-Target Effect of Gilteritinib With Venetoclax Decreases Tumor Burden for Patients With Relapsed/Refractory Wild-TypeCase reports in hematology · 2025Article
- Distinct clinical profiles and patient outcomes in aCML and CNL.Annals of hematology · 2024Article
- A Combinatorial Functional Precision Medicine Platform for Rapid Therapeutic Response Prediction in AML.Cancer medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 3 institutions in 2 countries.
Nora E RahmaniDepartment of Oncology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA.
Nandini RamachandraDepartment of Oncology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA.
Srabani SahuDepartment of Oncology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA.
Nadege GitegoDepartment of Biochemistry, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA.
Andrea LopezDepartment of Biochemistry, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA.
Kith PradhanDepartment of Oncology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA.
Tushar D BhagatDepartment of Oncology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA.
Shanisha Gordon-MitchellDepartment of Oncology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA.
Bianca Rivera PenaDepartment of Oncology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA.ORCID 0000-0001-8821-0210
Mohammad KazemiDepartment of Oncology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA.
Keshav RaoDepartment of Oncology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA.
Orsi GiriczDepartment of Oncology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA.ORCID 0000-0002-1328-3682
Shahina Bano MaqboolDepartment of Genetics, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA.
Raul OleaDepartment of Genetics, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA.
Yongmei ZhaoDepartment of Genetics, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA.
Jinghang ZhangDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA.ORCID 0000-0003-1436-6460
Hamid DolatshadBlood Cancer UK Molecular Haematology Unit, Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.ORCID 0000-0002-4724-1720
Vickram TittreaBlood Cancer UK Molecular Haematology Unit, Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
Dharamveer TatwavediBlood Cancer UK Molecular Haematology Unit, Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
Shalini SinghBlood Cancer UK Molecular Haematology Unit, Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
Juseong LeeBlood Cancer UK Molecular Haematology Unit, Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
Tianyu SunBlood Cancer UK Molecular Haematology Unit, Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.ORCID 0000-0002-8245-0771
Ulrich SteidlDepartment of Oncology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA.
Aditi ShastriDepartment of Oncology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA.ORCID 0000-0002-5366-8288
Daichi InoueHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Omar Abdel-WahabHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Andrea PellagattiBlood Cancer UK Molecular Haematology Unit, Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.ORCID 0000-0002-6122-0221
Evripidis GavathiotisDepartment of Biochemistry, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA. evripidis.gavathiotis@einstein.yu.edu.ORCID 0000-0001-6319-8331
Jacqueline BoultwoodBlood Cancer UK Molecular Haematology Unit, Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, UK. jacqueline.boultwood@ndcls.ox.ac.uk.ORCID 0000-0002-4330-2928
Amit VermaDepartment of Oncology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA. amit.verma@einsteinmed.org.ORCID 0000-0001-7592-7693
Albert Einstein College of Medicine · USUniversity of Oxford · GBMemorial Sloan Kettering Cancer Center · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MBronx-Einstein Training in Teaching and Research (BETTR), an IRACDA programK12GM102779 · NIGMS · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI Dianne Cox, Johanna Patricia Daily · 2012 to 2026
$9.2MSmall Molecule Activators of Pro-apoptotic BAX for Cancer TherapyR01CA178394 · NCI · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI GAVATHIOTIS, EVRIPIDIS · 2014 to 2024
$3.7MNCI NIH HHS P30 CA008748NCI NIH HHS R01 CA178394NIGMS NIH HHS K12 GM102779
Abstract
The BCL2-inhibitor, Venetoclax (VEN), has shown significant anti-leukemic efficacy in combination with the DNMT-inhibitor, Azacytidine (AZA). To explore the mechanisms underlying the selective sensitivity of mutant leukemia cells to VEN and AZA, we used cell-based isogenic models containing a common leukemia-associated mutation in the epigenetic regulator ASXL1. KBM5 cells with CRISPR/Cas9-mediated correction of the ASXL1
Indexed as
Antineoplastic AgentsAzacitidineBridged Bicyclo Compounds, HeterocyclicCell Line, TumorEpigenesis, GeneticGene Expression Regulation, LeukemicHumansLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMutationPoint MutationRepressor ProteinsSulfonamidesAntineoplastic AgentsASXL1 protein, humanAzacitidineBridged Bicyclo Compounds, HeterocyclicRepressor ProteinsSulfonamidesvenetoclax
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.